• Lunit will present five studies of its AI-powered pathology platform at ESMO 2026, scheduled for Oct. 23-27 in Madrid.
• Breast cancer research advanced to real-world clinical evaluation following comparative testing of AI tools for assessing HER2 expression.
• A lung cancer study found differences between manual and AI-based PD-L1 assessments, particularly at low expression levels.
• Pancreatic cancer research found that tissue characteristics had differing associations with survival depending on mutation status and tissue context.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lunit Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN76420) on October 20, 2026, and is solely responsible for the information contained therein.